Shaker Mousa

Shaker Mousa

Company: Nano-Pharmaceuticals

Job title: Professor ACPHS and Co-Founder

Seminars:

Delving into the Thyrointegrin Antagonist & Cancer Therapeutics 3:40 pm

Considering the challenges in developing novel strategies and the failure of previous avb3 antagonists in cancer therapy Pinpoint the problems with these in order to re-assess the MoAs Overcome these challenges to design novel therapeuticsRead more

day: Day One

An Analysis of Integrins for Nano-Targeted Delivery 1:30 pm

• Looking at the evidence which has demonstrated that nanobiotechnology and nanomedicine have tremendous potential to affect numerous aspects of cancer and other disorders, in both early diagnosis and targeted therapy • The utilization of nanotechnology for the development of new Nano-carrier systems has the potential to offer improved targeted delivery through increased solubility and…Read more

day: Day Two

Roundtable Discussion: 3:15 pm

Finish up your Integrin 101 day with an open discussion with our expert speakers to ensure all your questions are answered, including: The binding of integrins The role of integrins in autoimmune diseases, opthalmic disorders and moreRead more

day: Pre-Conference Focus Day

Chair’s Closing Remarks & End of Day Two
2:00 pm

Read more

day: Day Two

Chair’s Opening Remarks 8:50 am

Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.